|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pao W and Girard N: New driver mutations
in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reka AK, Goswami MT, Krishnapuram R,
Standiford TJ and Keshamouni VG: Molecular cross-regulation between
PPAR-γ and other signaling pathways: Implications for lung cancer
therapy. Lung Cancer. 72:154–159. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Haura EB, Turkson J and Jove R: Mechanisms
of disease: Insights into the emerging role of signal transducers
and activators of transcription in cancer. Nat Clin Pract Oncol.
2:315–324. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kamran MZ, Patil P and Gude RP: Role of
STAT3 in cancer metastasis and translational advances. BioMed Res
Int. 2013:4218212013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jatiani SS, Baker SJ, Silverman LR and
Reddy EP: Jak/STAT pathways in cytokine signaling and
myeloproliferative disorders: Approaches for targeted therapies.
Genes Cancer. 1:979–993. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu H and Jove R: The STATs of cancer—new
molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Looyenga BD, Hutchings D, Cherni I,
Kingsley C, Weiss GJ and Mackeigan JP: STAT3 is activated by JAK2
independent of key oncogenic driver mutations in non-small cell
lung carcinoma. PloS One. 7:e308202012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F,
Sawaya R and Huang S: Stat3 activation regulates the expression of
matrix metalloproteinase-2 and tumor invasion and metastasis.
Oncogene. 23:3550–3560. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu H, Pardoll D and Jove R: STATs in
cancer inflammation and immunity: A leading role for STAT3. Nat Rev
Cancer. 9:798–809. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Carpenter RL and Lo HW: STAT3 target genes
relevant to human cancers. Cancers (Basel). 6:897–925. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Debnath B, Xu S and Neamati N: Small
molecule inhibitors of signal transducer and activator of
transcription 3 (Stat3) protein. J Med Chem. 55:6645–6668. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Masciocchi D, Gelain A, Villa S,
Meneghetti F and Barlocco D: Signal transducer and activator of
transcription 3 (STAT3): A promising target for anticancer therapy.
Future Med Chem. 3:567–597. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hedvat M, Huszar D, Herrmann A, Gozgit JM,
Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, et
al: The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and
oncogenesis in solid tumors. Cancer Cell. 16:487–497. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sen M, Thomas SM, Kim S, Yeh JI, Ferris
RL, Johnson JT, Duvvuri U, Lee J, Sahu N, Joyce S, et al:
First-in-human trial of a STAT3 decoy oligonucleotide in head and
neck tumors: Implications for cancer therapy. Cancer Discov.
2:694–705. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Alas S and Bonavida B: Inhibition of
constitutive STAT3 activity sensitizes resistant non-Hodgkin's
lymphoma and multiple myeloma to chemotherapeutic drug-mediated
apoptosis. Clin Cancer Res. 9:316–326. 2003.PubMed/NCBI
|
|
17
|
Sledz CA and Williams BR: RNA interference
in biology and disease. Blood. 106:787–794. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stein CA: The experimental use of
antisense oligonucleotides: A guide for the perplexed. J Clin
Invest. 108:641–644. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin L, Hutzen B, Li PK, Ball S, Zuo M,
DeAngelis S, Foust E, Sobo M, Friedman L, Bhasin D, et al: A novel
small molecule, LLL12, inhibits STAT3 phosphorylation and
activities and exhibits potent growth-suppressive activity in human
cancer cells. Neoplasia. 12:39–50. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu A, Liu Y, Li PK, Li C and Lin J: LLL12
inhibits endogenous and exogenous interleukin-6-induced STAT3
phosphorylation in human pancreatic cancer cells. Anticancer Res.
31:2029–2035. 2011.PubMed/NCBI
|
|
21
|
Zuo M, Li C, Lin J and Javle M: LLL12, a
novel small inhibitor targeting STAT3 for hepatocellular carcinoma
therapy. Oncotarget. 6:10940–10949. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mankan AK and Greten FR: Inhibiting signal
transducer and activator of transcription 3: Rationality and
rationale design of inhibitors. Exp Opin Investig Drugs.
20:1263–1275. 2011. View Article : Google Scholar
|
|
23
|
Bid HK, Oswald D, Li C, London CA, Lin J
and Houghton PJ: Anti-angiogenic activity of a small molecule STAT3
inhibitor LLL12. PloS One. 7:e355132012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bishop JL, Thaper D and Zoubeidi A: The
multifaceted roles of STAT3 signaling in the progression of
prostate cancer. Cancers (Basel). 6:829–859. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Morikawa T, Baba Y, Yamauchi M, Kuchiba A,
Nosho K, Shima K, Tanaka N, Huttenhower C, Frank DA, Fuchs CS and
Ogino S: STAT3 expression, molecular features, inflammation
patterns, and prognosis in a database of 724 colorectal cancers.
Clin Cancer Res. 17:1452–1462. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C
and Lin J: STAT3 is necessary for proliferation and survival in
colon cancer-initiating cells. Cancer Res. 71:7226–7237. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiong H, Du W, Wang JL, Wang YC, Tang JT,
Hong J and Fang JY: Constitutive activation of STAT3 is predictive
of poor prognosis in human gastric cancer. J Mol Med(Berl).
90:1037–1046. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ryu K, Choy E, Yang C, Susa M, Hornicek
FJ, Mankin H and Duan Z: Activation of signal transducer and
activator of transcription 3 (Stat3) pathway in osteosarcoma cells
and overexpression of phosphorylated-Stat3 correlates with poor
prognosis. J Orthopaed Res. 28:971–978. 2010.
|
|
29
|
Schoppmann SF, Jesch B, Friedrich J,
Jomrich G, Maroske F and Birner P: Phosphorylation of signal
transducer and activator of transcription 3 (STAT3) correlates with
Her-2 status, carbonic anhydrase 9 expression and prognosis in
esophageal cancer. Clin Exp Metastasis. 29:615–624. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ball S, Li C, Li PK and Lin J: The small
molecule, LLL12, inhibits STAT3 phosphorylation and induces
apoptosis in medulloblastoma and glioblastoma cells. PloS One.
6:e188202011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lin L, Benson DM Jr, DeAngelis S, Bakan
CE, Li PK, Li C and Lin J: A small molecule, LLL12 inhibits
constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits
potent growth suppressive activity in human multiple myeloma cells.
Int J Cancer. 130:1459–1469. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Onimoe GI, Liu A, Lin L, Wei CC, Schwartz
EB, Bhasin D, Li C, Fuchs JR, Li PK, Houghton P, et al: Small
molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent
growth suppressive activity in osteosarcoma cells and tumor growth
in mice. Invest New Drugs. 30:916–926. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Couto JI, Bear MD, Lin J, Pennel M, Kulp
SK, Kisseberth WC and London CA: Biologic activity of the novel
small molecule STAT3 inhibitor LLL12 against canine osteosarcoma
cell lines. BMC Vet Res. 8:2442012. View Article : Google Scholar : PubMed/NCBI
|
